Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer

Molecular Medicine

Volumn 17, Issue 5-6, 2011, Pages 333-352

  Dinarello, Charles A ^a,b   Fossati, Gianluca ^c   Mascagni, Paolo ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Italfarmaco SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; CHEMOKINE RECEPTOR CXCR4; CXCL9 CHEMOKINE; DACINOSTAT; DEXAMETHASONE; ETANERCEPT; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GIVINOSTAT; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; PANOBINOSTAT; PROTEIN BCL 2; ROMIDEPSIN; STAT3 PROTEIN; STEROID; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID; VORINOSTAT;

ACETYLATION; AMYOTROPHIC LATERAL SCLEROSIS; ANEMIA; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTHROPATHY; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOPHAGY; BINDING AFFINITY; CELL PROLIFERATION; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DEMENTIA; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENTEROPATHY; ENZYME INHIBITION; EPILEPSY; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTINGTON CHOREA; INSULIN RELEASE; JUVENILE RHEUMATOID ARTHRITIS; LEUKEMIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOMA; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MULTIPLE MYELOMA; MUSCULAR DYSTROPHY; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OCCLUSIVE CEREBROVASCULAR DISEASE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RISK FACTOR; SCHNITZLER SYNDROME; SEPTIC SHOCK; SICKLE CELL ANEMIA; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS; HISTONE DEACETYLASE INHIBITORS; HIV INFECTIONS; HUMANS; NEOPLASMS; NEURODEGENERATIVE DISEASES;

EID: 79957951510     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00116     Document Type: Article

References (177)

1. Dinarello CA. (2010) Anti-inflammatory agents: present and future. Cell. 140:935-950.
2. Mandrup-Poulsen T, Pickersgill L, Donath MY. (2010) Blockade of interleukin 1 in Type 1 diabetes mellitus. Nat. Rev. Endocrinol. 6:158-166.
3. Donath MY, Shoelson SE. (2011) Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11:98-107.
4. Dinarello CA, Donath MY, Mandrup-Poulsen T. (2010) Role of IL-1beta in Type 2 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 17:314-321.
5. Vojinovic J, et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemiconset juvenile idiopathic arthritis. Arthritis Rheum. 63:1452-1458.
6. Lewis EC, et al. (2011) The oral histone deacety-lase inhibitor ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro. Mol. Med. 17:369-377.
7. Khan N, et al. (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409:581-589.
8. Wang WC. (2008) The pharmacotherapy of sickle cell disease. Expert Opin. Pharmacother. 9:3069-3082.
9. Hines P, Dover GL, Resar LM. (2008) Pulsed-dos-ing with oral sodium phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia. Pediatric Blood Cancer. 50:357-359.
10. Leoni F, et al. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. U.S.A. 99:2995-3000.
11. Leoni F, et al. (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 11:1-15.
12. Curtin M, Glaser K. (2003) Histone deacetylase inhibitors: the Abbott experience. Curr. Med. Chem. 10:2373-2392.
13. Montgomery RL, et al. (2007) Histone deacety-lases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 21:1790-1802.
14. Haberland M, Mokalled MH, Montgomery RL, Olson EN. (2009) Epigenetic control of skull morphogenesis by histone deacetylase 8. Genes Dev. 23:1625-1630.
15. Knutson SK, et al. (2008) Liver-specific deletion of histone deacetylase 3 disrupts metabolic tran-scriptional networks. EMBO J. 27:1017-1028.
16. Klampfer L, Huang J, Swaby LA, Augenlicht L. (2004) Requirement of histone deacetylase activity for signaling by STAT1. J. Biol. Chem. 279:30358-30368.
17. Dinarello CA. (2011) Interleukin-1 in the patho-genesis and treatment of inflammatory diseases. Blood. 117:3720-3732.
18. Hoffman HM, Wanderer AA. Inflammasome and IL-1beta-mediated disorders. Curr. Allergy Asthma Rep. 10:229-235.
19. Matalon S, et al. (2010) The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and mono-cytes and is superior to valproic acid for latent HIV-1 expression in vitro. J. Acquir. Immune Defic. Syndr. 54:1-9.
20. Bosisio D, et al. (2008) Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J. Leukoc. Biol. 84:1540-1548.
21. Wang H, et al. (2011) Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J. Immunol. 186:3986-3996.
22. Song W, et al. (2010) HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia. 25:161-168.
23. Grabiec AM, et al. (2010) Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J. Immunol. 184:2718-2728.
24. Grabiec AM, Tak PP, Reedquist KA. (2011) His-tone deacetylase inhibitors suppress IL-6 production by rheumatoid arthritis fibroblast-like syn-oviocytes and macrophages via modulation of mRNA stability rather than blockade of NFkB signalling. Ann. Rheum. Dis. 70 Suppl 2:A30-A31.
25. Joosten LAB, Leoni F, Meghji S, Mascagni P. (2011) Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis. Mol. Med. 17:391-396.
26. Vojinovic J, Damjanov N. (2011) HDAC inhibition in rheumatoid arthritis and juvenile idio-pathic arthritis. Mol. Med. 17:397-403.
27. Chen CJ, et al. (2007) Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 13:851-856.
28. Cohen I, et al. (2010) Differential release of chro-matin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc. Natl. Acad. Sci. U. S. A. 107:2574-2579.
29. Scaffidi P, Misteli T, Bianchi ME. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418:191-195.
30. Miossec P, Korn T, Kuchroo VK. (2009) Inter-leukin-17 and type 17 helper T cells. N. Engl. J. Med. 361:888-898.
31. Donath MY, Storling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T. (2008) Cytokines and beta-cell biology: from concept to clinical translation. Endocr. Rev. 29:334-350.
32. Larsen L, et al. (2007) Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia. 50:779-789.
33. Susick L, Veluthakal R, Suresh MV, Hadden T, Kowluru A. (2007) Regulatory roles for histone deacetylation in IL-1beta-induced nitric oxide release in pancreatic beta-cells. J. Cell Mol. Med. 5:5.
34. Christensen D P, et al. (2011) Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus. Mol. Med. 17:378-390.
35. Lundh M, et al. (2010) Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines. Diabetologia. 53:2569-2578.
36. Patel T, Patel V, Singh R, Jayaraman S. (2011) Chromatin remodeling resets the immune system to protect against autoimmune diabetes in mice. Immunol. Cell Biol. 2011, Feb 15 [Epub ahead of print].
37. Koulmanda M, et al. (2008) Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc. Natl. Acad. Sci. U. S. A. 105:16242-16247.
38. Matalon S, Rasmussen TA, Dinarello CA. (2011) Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol. Med. 17:466-472.
39. Crazzolara R, et al. (2002) Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lym-phoblastic leukaemia. Br. J. Haematol. 119:965-969.
40. Larsen CM, et al. (2007) Interleukin-1-receptor antagonist in Type 2 diabetes mellitus. N. Engl. J. Med. 356:1517-1526.
41. Faraco G, et al. (2009) Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol. Dis. 36:269-279.
42. Green SR, Choudhary AK, Fleming IN. (2009) Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types. Br. J. Cancer. 103:1391-1399.
43. Choi S, Reddy P. (2011) HDAC inhibition and graft versus host disease. Mol. Med. 17:404-416.
44. Reddy P, et al. (2008) Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 118:2562-2573.
45. Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 325:834-840.
46. Calao M, Burny A, Quivy V, Dekoninck A, Van Lint C. (2008) A pervasive role of histone acetyl-transferases and deacetylases in an NF-kappaB-signaling code. Trends Biochem. Sci. 33:339-349.
47. Chen LF, Mu Y, Greene WC. (2002) Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J. 21:6539-6548.
48. Chen L, Fischle W, Verdin E, Greene WC. (2001) Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 293:1653-1657.
49. Kiernan R, et al. (2003) Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J. Biol. Chem. 278:2758-2766.
50. Bode KA, et al. (2007) Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology. 122:596-606.
51. Cao W, Bao C, Padalko E, Lowenstein CJ. (2008) Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J. Exp. Med. 205:1491-1503.
52. Carta S, et al. (2006) Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of micro-tubules. Blood. 108:1618-1626.
53. Martinon F, Mayor A, Tschopp J. (2009) The in-flammasomes: guardians of the body. Annu. Rev. Immunol. 27:229-265.
54. Into T, Inomata M, Niida S, Murakami Y, Shibata K. (2010) Regulation of MyD88 aggregation and the MyD88-dependent signaling pathway by se-questosome 1 and histone deacetylase 6. J. Biol. Chem. 285:35759-35769.
55. Li Y, et al. (2010) Surviving lethal septic shock without fluid resuscitation in a rodent model. Surgery. 148:246-254.
56. Brogdon JL, et al. (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood. 109:1123-1130.
57. Roger T, et al. (2011) Histone deacetylase in-hibitors impair innate immune responses to Tolllike receptor agonists and to infection. Blood. 117:1205-1217.
58. Ramirez-Carrozzi VR, et al. (2006) Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome remodeling complexes during an inflammatory response. Genes Dev. 20:282-296.
59. Calabrese F, et al. (2008) IL-32, a novel proinflam-matory cytokine in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 178:894-901.
60. Ito K, et al. (2005) Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 352:1967-1976.
61. Mizuno S, et al. (2010) Inhibition of histone deacetylase causes emphysema. Am. J. Physiol. Lung Cell Mol. Physiol. 300:L402-L413.
62. Dinarello CA. (2005) Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J. Rheumatol. Suppl. 74:40-47.
63. McKinsey TA. (2011) Targeting inflammation in heart failure with histone deacetylase inhibitors. Mol. Med. 17:434-441.
64. Abbate A, et al. (2010) Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur. J. Heart Fail. 12:319-322.
65. Abbate A, et al. (2010) Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction. Am. J. Cardiol. 105:1371-1377.
66. Deswal A, et al. (1999) Safety and efficacy of a soluble P75 tumor necrosis factor receptor (En-brel, etanercept) in patients with advanced heart failure. Circulation. 99:3224-3226.
67. Mann DL. (2002) Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 91:988-998.
68. Di Iorio A, et al. (2003) Serum IL-1beta levels in health and disease: a population-based study: "The InCHIANTI study." Cytokine. 22:198-205.
69. Abbate A, et al. (2008) Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation. 117:2670-2683.
70. Joosten LA, et al. (1999) IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J. Immunol. 163:5049-5055.
71. Reddy P, et al. (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl. Acad. Sci. U. S. A. 101:3921-3926.
72. Sun Y, et al. (2009) Cutting edge: negative regulation of dendritic cells through acetylation of the nonhis-tone protein STAT-3. J. Immunol. 182:5899-5903.
73. Bodar EJ, Simon A, van der Meer JWM. (2011) Effects of the histone deacetylase inhibitor ITF2357 in autoinflammatory syndromes. Mol. Med. 17:363-368.
74. Glauben R, Siegmund B. (2011) Inhibition of his tone deacetylases in inflammatory bowel diseases. Mol. Med. 17:426-433.
75. Reilly CM, Regna N, Mishra N. (2011) HDAC inhibition in lupus models. Mol. Med. 17:417-425.
76. Faraco G, Cavone L, Chiarugi A. (2011) The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis. Mol. Med. 17:442-447.
77. Shein NA, Shohami E. (2011) Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries. Mol. Med. 17:448-456.
78. Consalvi S, et al. (2011) Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases. Mol. Med. 17:457-465.
79. Halili MA, Andrews MR, Sweet MJ, Fairlie DP. (2009) Histone deacetylase inhibitors in inflammatory disease. Curr. Top. Med. Chem. 9:309-319.
80. Choi JH, et al. (2005) Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25:2404-2409.
81. Halili MA, et al. (2010) Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J. Leukoc. Biol. 87:1103-1114.
82. Zayed N, et al. (2008) Inhibition of interleukin-1beta-induced matrix metalloproteinases 1 and 13 production in human osteoarthritic chondrocytes by prostaglandin D2. Arthritis Rheum. 58:3530-3540.
83. Yamaguchi K, Lantowski A, Dannenberg AJ, Sub-baramaiah K. (2005) Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. J. Biol. Chem. 280:32569-32577.
84. Aung HT, et al. (2006) LPS regulates proinflam-matory gene expression in macrophages by altering histone deacetylase expression. FASEB J. 20:1315-1327.
85. Garcia-Manero G, et al. (2008) Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodys-plastic syndromes. Blood. 111:1060-1066.
86. O'Connor OA, et al. (2006) Clinical experience with intravenous and oral formulations of the novel his-tone deacetylase inhibitor suberoylanilide hydrox-amic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24:166-173.
87. Furlan A, et al. (2011) Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol. Med. 17:353-362.
88. Lin T, et al. (2006) Cardiac histones are substrates of histone deacetylase activity in hemorrhagic shock and resuscitation. Surgery. 139:365-376.
89. Sailhamer EA, et al. (2008) Acetylation: a novel method for modulation of the immune response following trauma/hemorrhage and inflammatory second hit in animals and humans. Surgery. 144:204-216.
90. Terkeltaub R, et al. (2009) The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monose-quence crossover, non-randomised, single-blind pilot study. Ann. Rheum. Dis. 68:1613-1617.
91. So A, De Smedt T, Revaz S, Tschopp J. (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9:R28.
92. So A, et al. (2010) Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 62:3064-3076.
93. Shein NA, et al. (2009) Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J. 23:4266-4275.
94. Kozikowski AP, et al. (2009) Searching for disease modifiers-PKC activation and HDAC inhibition: a dual drug approach to Alzheimer's disease that decreases Abeta production while blocking oxidative stress. Chem. Med. Chem. 4:1095-1105.
95. Ona VO, et al. (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399:263-267.
96. Hockly E, et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 100:2041-2046.
97. Benn CL, et al. (2009) Genetic knock-down of HDAC7 does not ameliorate disease pathogene-sis in the R6/2 mouse model of Huntington's disease. PLoS One. 4:e5747.
98. Chuang DM. (2005) The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann. N. Y. Acad. Sci. 1053:195-204.
99. Dompierre JP, et al. (2007) Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci. 27:3571-3583.
100. Meissner F, Molawi K, Zychlinsky A. (2010) Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc. Natl. Acad. Sci. U. S. A. 107:13046-13050.
101. van der Meer JW, Simon A. (2010) Blocking IL-1beta to slow down progression of ALS? Proc. Natl. Acad. Sci. U. S. A. 107:12741-12742.
102. Lust JA, et al. (2009) Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin. Proc. 84:114-122.
103. Dinarello CA. (2009) Targeting the pathogenic role of interleukin 1beta in the progression of smoldering/indolent myeloma to active disease. Mayo Clin. Proc. 84:105-107.
104. Golay J, et al. (2007) The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia. 21:1892-1900.
105. Rambaldi A, et al. (1991) Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood. 78:3248-53.
106. Lust JA, Donovan KA. (1999) The role of inter-leukin-1 beta in the pathogenesis of multiple myeloma. Hematol. Oncol. Clin. North Am. 13:1117-1125.
107. Galli M, et al. (2010) A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann. Hematol. 89:185-190.
108. Todoerti K, et al. (2010) Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica. 95:260-269.
109. Rambaldi A, et al. (2010) A pilot study of the his-tone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloprolifer-ative neoplasms. Br. J. Haematol. 150:446-455.
110. Guerini V, et al. (2008) The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia. 22:740-747.
111. Hansen ER, Vejlsgaard GL, Lisby S, Heidenheim M, Baadsgaard O. (1991) Epidermal interleukin 1 alpha functional activity and interleukin 8 im-munoreactivity are increased in patients with cutaneous T-cell lymphoma. J. Invest. Dermatol. 97:818-823.
112. Bladon J, Taylor PC. (2006) The down-regulation of IL1alpha and IL6, in monocytes exposed to extracorporeal photopheresis (ECP)-treated lymphocytes, is not dependent on lymphocyte phos-phatidylserine externalization. Transpl. Int. 19:319-324.
113. Tilg H, et al. (1993) Induction of circulating IL-1 receptor antagonist by IFN treatment. J. Immunol. 150:4687-4692.
114. Gerstner T, Bell N, Konig S. (2008) Oral valproic acid for epilepsy: long-term experience in therapy and side effects. Expert Opin. Pharmacother. 9:285-292.
115. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neu-rochem. 89:1358-1367.
116. Archin NM, et al. (2008) Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS. 22:1131-1135.
117. Atweh GF, Schechter AN. (2001) Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr. Opin. Hematol. 8:123-130.
118. Bodar EJ, Simon A, van der Meer JWM. (2011) Effects of the histone deacetylase inhibitor ITF2357 in autoinflammatory syndromes. Mol. Med. 17:363-368.
119. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilke-son GS. (2003) Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 111:539-552.
120. Reilly CM, et al. (2004) Modulation of renal disease in MRL/lpr mice by suberoylanilide hy-droxamic acid. J. Immunol. 173:4171-4178.
121. Robert T, et al. (2011) HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature. 471:74-79.
122. Hur KY, Jung HS, Lee MS. (2010) Role of au-tophagy in beta-cell function and mass. Diabetes Obes. Metab. 12 Suppl 2:20-26.
123. Vanhorebeek I, et al. (2011) Insufficient activation of autophagy allows cellular damage to accumulate in critically ill patients. J. Clin. Endocrinol. Metab. 96:E633-E645.
124. Cao DJ, et al. (2011) Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc. Natl. Acad. Sci. U. S. A. 108:4123-4128.
125. Bogaard HJ, et al. (2011) Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am. J. Respir. Crit. Care Med. 2011, Feb 4 [Epub ahead of print].
126. Daosukho C, et al. (2007) Phenylbutyrate, a his-tone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury. Free Radic. Biol. Med. 42:1818-1825.
127. Granger A, et al. (2008) Histone deacetylase inhibition reduces myocardial ischemia-reperfu-sion injury in mice. FASEB J. 22:3549-3560.
128. Davey RT Jr, et al. (1999) HIV-1 and T cell dynamics after interruption of highly active anti-retroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl. Acad. Sci. U. S. A. 96:15109-15114.
129. Chun TW, et al. (2005) HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J. Clin. Invest. 115:3250-3255.
130. Richman DD, et al. (2009) The challenge of finding a cure for HIV infection. Science. 323:1304-1307.
131. Archin NM, et al. (2010) Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One. 5:e9390.
132. Archin NM, et al. (2009) Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS. 23:1799-1806.
133. Archin NM, et al. (2009) Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses. 25:207-212.
134. Bishton MJ, et al. (2011) Deciphering the molecular and biological processes that mediate his-tone deacetylase inhibitor-induced thrombocy-topenia. Blood. 117:3658-3668.
135. Whittaker SJ, et al. (2010) Final results from a multicenter, international, pivotal study of ro-midepsin in refractory cutaneous T-cell lym-phoma. J. Clin. Oncol. 28:4485-4491.
136. Choi Y, et al. (2008) Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo en-dotoxemia model. Exp. Mol. Med. 40:574-581.
137. Inoue K, et al. (2006) Histone deacetylase inhibitor reduces monocyte adhesion to endothe-lium through the suppression of vascular cell adhesion molecule-1 expression. Arterioscler. Thromb. Vasc. Biol. 26:2652-2659.
138. Su RC, Becker AB, Kozyrskyj AL, Hayglass KT. (2008) Epigenetic regulation of established human type 1 versus type 2 cytokine responses. J. Allergy Clin. Immunol. 121:57-63.e3.
139. Choi JC, Holtz R, Murphy S P. (2009) Histone deacetylases inhibit IFN-gamma-inducible gene expression in mouse trophoblast cells. J. Immunol. 182:6307-6315.
140. Chabane N, et al. (2008) Histone deacetylase inhibitors suppress interleukin-1beta-induced nitric oxide and prostaglandin E2 production in human chondrocytes. Osteoarthritis Cartilage. 16:1267-1274.
141. Crosson CE, Mani SK, Husain S, Alsarraf O, Menick DR. (2010) Inhibition of histone deacetylase protects the retina from ischemic injury. Invest. Ophthalmol. Vis. Sci. 51:3639-3645.
142. Iwata K, et al. (2002) Trichostatin A, a histone deacetylase inhibitor, down-regulates inter-leukin-12 transcription in SV-40-transformed lung epithelial cells. Cell Immunol. 218:26-33.
143. Glauben R, et al. (2008) Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut. 57:613-622.
144. Glauben R, et al. (2006) Histone hyperacetyla-tion is associated with amelioration of experimental colitis in mice. J. Immunol. 176:5015-5022.
145. de Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW. (2010) Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology. 138:583-594.
146. Tong X, Yin L, Giardina C. (2004) Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition. Biochem. Biophys. Res. Commun. 317:463-471.
147. Leng C, et al. (2006) Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp. Hematol. 34:776-787.
148. Tao R, et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13:1299-1307.
149. Wang L, Tao R, Hancock WW. (2009) Using his-tone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance. Immunol. Cell Biol. 87:195-202.
150. Edens RE, Dagtas S, Gilbert KM. (2006) Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. Int. Immunopharmacol. 6:1673-1681.
151. Tao R, et al. (2007) Histone deacetylase inhibitors and transplantation. Curr. Opin. Immunol. 19:589-595.
152. Camelo S, et al. (2005) Transcriptional therapy with the histone deacetylase inhibitor tricho-statin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 164:10-21.
153. Jung ID, et al. (2009) Apicidin, the histone deacetylase inhibitor, suppresses Th1 polarization of murine bone marrow-derived dendritic cells. Int. J. Immunopathol. Pharmacol. 22:501-515.
154. Matsuoka H, Fujimura T, Mori H, Aramori I, Mutoh S. (2007) Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells. Int. Immunopharmacol. 7:1422-1432.
155. Matsuoka H, et al. (2007) Disruption of HDAC4/N-CoR complex by histone deacety-lase inhibitors leads to inhibition of IL-2 gene expression. Biochem. Pharmacol. 74:465-476.
156. Moreira JM, Scheipers P, Sorensen P. (2003) The histone deacetylase inhibitor trichostatin A modulates CD4+ T cell responses. BMC Cancer. 3:30.
157. Skov S, et al. (2003) Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression. Blood. 101:1430-1438.
158. Lin HS, et al. (2007) Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150:862-872.
159. Saouaf SJ, et al. (2009) Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp. Mol. Pathol. 87:99-104.
160. Choo QY, Ho PC, Tanaka Y, Lin HS. (2010) His-tone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells. Rheumatology (Oxford). 49:1447-1460.
161. Guo W, Shan B, Klingsberg RC, Qin X, Lasky JA. (2009) Abrogation of TGF-beta1-induced fi-broblast-myofibroblast differentiation by his-tone deacetylase inhibition. Am. J. Physiol. Lung Cell Mol. Physiol. 297:L864-L870.
162. Wang X, Song Y, Jacobi JL, Tuan RS. (2009) Inhibition of histone deacetylases antagonized FGF2 and IL-1beta effects on MMP expression in human articular chondrocytes. Growth Factors. 27:40-49.
163. Kook H, et al. (2003) Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical home-odomain protein Hop. J. Clin. Invest. 112:863-871.
164. Zhang CL, et al. (2002) Class II histone deacety-lases act as signal-responsive repressors of cardiac hypertrophy. Cell. 110:479-488.
165. Colussi C, et al. (2011) The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice. Cardiovasc. Res. 87:73-82.
166. Chen PS, et al. (2007) Valproic acid and other hi-stone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-in-duced dopaminergic neurotoxicity. Neuroscience. 149:203-212.
167. Faraco G, et al. (2006) Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol. 70:1876-1884.
168. Kim HJ, et al. (2007) Histone deacetylase inhibitors exhibit anti-inflammatory and neuro-protective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 321:892-901.
169. Anne-Laurence B, Caroline R, Irina P, Jean-Philippe L. (2007) Chromatin acetylation status in the manifestation of neurodegenerative diseases: HDAC inhibitors as therapeutic tools. Subcell. Biochem. 41:263-293.
170. Janssen C, et al. (2010) Differential histone deacetylase mRNA expression patterns in amy-otrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 69:573-581.
171. Susick L, Senanayake T, Veluthakal R, Woster PM, Kowluru A. (2009) A novel histone deacetylase inhibitor prevents IL-1beta induced metabolic dysfunction in pancreatic beta-cells. J. Cell Mol. Med. 13:1877-1885.
172. Kinugasa F, et al. (2010) Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction. Transpl. Immunol. 23:18-23.
173. Marumo T, Hishikawa K, Yoshikawa M, Fujita T. (2008) Epigenetic regulation of BMP7 in the regenerative response to ischemia. J. Am. Soc. Nephrol. 19:1311-1320.
174. Marumo T, et al. (2011) Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury. Am. J. Phys-iol. Renal Physiol. 298:F133-F141.
175. Mie Lee Y, et al. (2003) Inhibition of hypoxia-induced angiogenesis by FK228, a specific his-tone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem. Biophys. Res. Com-mun. 300:241-246.
176. Noh H, et al. (2009) Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am. J. Physiol. Renal Physiol. 297:F729-F739.
177. Yoshikawa M, Hishikawa K, Marumo T, Fujita T. (2007) Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J. Am. Soc. Nephrol. 18:58-65.